Research programme: biologics - Adlai Nortye

Drug Profile

Research programme: biologics - Adlai Nortye

Alternative Names: AN 3015; AN 6005

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adlai Nortye
  • Class Antibodies; Antineoplastics; Hepatoprotectants
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Non-alcoholic steatohepatitis; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 28 Nov 2017 Early research in Cancer in China (unspecified route)
  • 28 Nov 2017 Early research in Non-alcoholic steatohepatitis in China (unspecified route)
  • 28 Nov 2017 Early research in Non-small cell lung cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top